Skip to content

Prevalence of Hypoglycaemia in Congenital Adrenal Insufficiency

Prevalence of Hypoglycaemia in Congenital Adrenal Insufficiency

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04322435
Acronym
GLYSUR
Enrollment
9
Registered
2020-03-26
Start date
2020-07-15
Completion date
2022-08-31
Last updated
2026-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adrenal Insufficiency, Congenital

Keywords

Congenital primary and secondary adrenal insufficiency, Cortisol deficiency, Hypoglycaemia, Children

Brief summary

Children with congenital primary and secondary adrenal insufficiency, who are deficient in cortisol, are at risk for hypoglycaemia, irrespective of appropriate hydrocortisone treatment, which can lead to potentially serious neurological complications. Few series are described in pediatrics. The prevalence of hypoglycaemia is probably underestimated because it is often asymptomatic and capillary blood glucose monitoring is not always performed routinely. The objective of the study is to evaluate the prevalence of hypoglycaemia in children with adrenal insufficiency.

Detailed description

Children with congenital primary and secondary adrenal insufficiency, who are deficient in cortisol, are at risk for hypoglycaemia, irrespective of appropriate hydrocortisone treatment, which can lead to potentially serious neurological complications. Few series are described in pediatrics. The prevalence of hypoglycaemia is underestimated because it is often asymptomatic and capillary blood glucose monitoring is not always performed routinely. The objective of the study is to evaluate the prevalence of hypoglycaemia in children with congenital adrenal insufficiency. The study will follow for one year children from 6 months to 6 years, with central and peripheral adrenal insufficiency. 4 study times are planned with two measurement methods: * Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals. * Measurement of capillary blood glucose, in the morning on an empty stomach, every first week of each month for 12 months, with Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the test strips Accu-Chek performed. * Measurement of capillary glycaemia in case of suspicion of hypoglycaemia. Measure left free according to the judgment of the parents of the necessary character or not. With Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek performa strips.

Interventions

OTHERContinuous blood glucose measurement

Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.

OTHERMeasurement of capillary blood glucose

Measurement of capillary blood glucose : * In the morning on an empty stomach, every first week of each month for 12 months. * In case of suspicion of hypoglycaemia (parental assessment). Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips.

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER
URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Months to 6 Years
Healthy volunteers
No

Inclusion criteria

* All male and female patients, followed in the Paediatric Endocrinology Department at Necker Hospital, with congenital primary and secondary adrenal insufficiency. * Age between 6 months and 6 years. * Included in the social security system. * Parental consent and willingness to participate in this study: involves training and skills in the use of blood glucometers.

Exclusion criteria

* Patients with acquired adrenal insufficiency. * Patients with type 1 or type 2 diabetes. * Patients with somatotropic deficiency associated with adrenal insufficiency. * Refusal or impossibility to perform the glycaemic measurements according to the procedure of the study. * Not covered by the social security system.

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of hypoglycaemia1 yearNumber of hypoglycaemic events. Hypoglycaemia will be defined by a glucose level measured at a glucose level of less than or equal to 0.55 g /L (3 mmol /L).

Secondary

MeasureTime frameDescription
Duration of hypoglycaemia1 yearTime in hypoglycaemia measured in minutes per day during the continuous blood glucose measurements.
Percentage of time in hypoglycaemia1 yearPercentage of time in hypoglycaemia during the continuous blood glucose measurements.
Glycemic variations rate1 yearGlycemic variations rate during the different measurements times: minimum rate, maximum rate, average, median. Each result will be expressed in g /L or in mmol /L. Each date will expressed by one day and for one week.
Circumstances of occurrence of hypoglycaemia1 yearCircumstances in which hypoglycaemia occurred : descriptive data by parents, symptomatic or not symptomatic hypoglycaemia, descriptive signs if they are presents.
Occurrence of medical events1 yearEvents during the follow-up of the study: modification of treatment of hydrocortisone and fludrocortisone, re-sugaring expressed in number of sugar cubes ( by sugar cube = 20 gr of sugar) or type of sweet food given to the child, hospitalizations ( type and reason for hospitalization, cause of the decompensation).
Body Mass Index1 yearBody mass divided by the square of the body height expressed in units of kg/m2 : mass in kilograms and height in meters
Systolic and Diastolic Blood Pressure1 yearExpressed millimetre of mercury
Heart rate1 yearNumber of beats per minute
Stade tanner1 yearstade tanner A1 to A5
Amount of salt consumed per day1 yearNumber of grams per day
Cortisol at 8 a.m.1 yearmicrogram / deciliter
Cycle of 17-hydroxyprogesterone1 yearNanomole per liter
Adreno CorticoTropic Hormone1 yearNanogram per liter
17-hydroxyprogesterone1 yearNanomole per liter
Delta-4-Androstenedione1 yearNanomole per liter
Testosterone1 yearNanomole per liter
Ionogram1 yearNanomole per liter
Renin1 yearpicogram/milliliter

Countries

France

Contacts

PRINCIPAL_INVESTIGATORDinane Samara-Boustani, MD

Assistance Publique - Hôpitaux de Paris

STUDY_DIRECTORMichel Polak, MD, PhD

Assistance Publique - Hôpitaux de Paris

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026